| 09/08/2026 3:38 PM | Dyne Therapeutics (1818794) Subject Kerr Douglas (1814189) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/08/2026 3:39 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/08/2026 3:13 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/08/2026 3:14 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/08/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Friedl-Naderer Johanna (1915598) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/17/2026 4:30 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/17/2026 3:06 PM | Dyne Therapeutics (1818794) Issuer Lucera Erick (1697616) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/17/2026 3:07 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/14/2026 4:46 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2026 4:47 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2026 4:47 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for DYN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/13/2026 4:36 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:36 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:36 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:03 PM | Dyne Therapeutics (1818794) Subject Kerr Douglas (1814189) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:03 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:04 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 3:51 PM | Atlas Venture Fund XI, L.P. (1708269) Filed by Dyne Therapeutics (1818794) Subject | Form SCHEDULE 13G/A | |
| 08/13/2026 11:47 AM | Dyne Therapeutics (1818794) Subject Janus Henderson Group Ltd. (1274173) Filed by | Form SCHEDULE 13G/A | |
| 08/06/2026 9:20 AM | Dyne Therapeutics (1818794) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 07/22/2026 4:19 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/22/2026 4:21 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 07/21/2026 4:22 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 07/20/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/08/2026 4:35 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/07/2026 4:05 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:05 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:06 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:06 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/30/2026 6:05 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/29/2026 4:49 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:50 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:50 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 7:40 AM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/25/2026 4:28 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Earth's biggest energy source: near Grand Canyon (Ad) The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon.
A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years. See the company sitting on the biggest energy source on Earth |
| 06/25/2026 4:29 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:29 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:11 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:32 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:33 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:36 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 3:27 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/23/2026 5:25 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:26 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:19 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 06/23/2026 3:07 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/17/2026 3:03 PM | Dyne Therapeutics (1818794) Subject ForDyne B.V. (2019392) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/17/2026 3:07 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/09/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Stehman-Breen Catherine (1702233) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Incerti Carlo (1915358) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:15 PM | Dyne Therapeutics (1818794) Issuer HURWITZ EDWARD (1211840) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:06 PM | Dyne Therapeutics (1818794) Issuer Posner Brian S (1372455) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 3:05 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 11:36 AM | Dyne Therapeutics (1818794) Subject JANUS HENDERSON GROUP PLC (1274173) Filed by | Form SCHEDULE 13G/A | |
| 05/14/2026 3:04 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Friedl-Naderer Johanna (1915598) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/13/2026 3:55 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/13/2026 3:57 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 6:25 AM | Dyne Therapeutics (1818794) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/11/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/06/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/06/2026 3:42 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 10:13 AM | Dyne Therapeutics (1818794) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 05/05/2026 3:36 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:36 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:37 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 4:00 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/30/2026 4:22 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:56 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:43 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
The $15 Gold Fund That Pays Up to $1,152/Month (Ad) Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. Discover the gold income fund before the next payout date |
| 04/28/2026 3:44 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 5:15 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/27/2026 3:48 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:48 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:48 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:49 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:45 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:46 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:46 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |